Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Azacitidine
Related studies linked through entity extraction aliases.
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Status
- RECRUITING
- Phase
- PHASE1
Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients
- Status
- COMPLETED
- Phase
- NA
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
- Status
- RECRUITING
- Phase
- PHASE2
Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
- Status
- RECRUITING
- Phase
- PHASE2
Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
- Status
- RECRUITING
- Phase
- PHASE2
Demethylating Agent Azacitidine on Prevention of Acute Kidney Injury-chronic Kidney Disease Continuum
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Venetoclax Basket Trial for High Risk Hematologic Malignancies
- Status
- RECRUITING
- Phase
- PHASE1
Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML
- Status
- UNKNOWN
- Phase
- NA
AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Status
- RECRUITING
- Phase
- PHASE3